IP Library › Granted Patent US 9,988,628
Granted Patent B2
US 9,988,628 · App. 15/047,258 · Granted Jun 5, 2018

Agents useful in treating facioscapulohumeral muscular dystrophy

Inventors: Alexandra Belayew (Tilff, BE); Frederique Coppee (Havre, BE); Celine Vanderplanck (Asquillies, BE); Stephen Donald Wilton (Applecross, AU); Eugenie Ansseau (Dour, BE)
Assignee: UNIVERSITE DE MONS
C12N15/113C12N15/111C12N2310/11C12N2310/14C12N2310/315C12N2310/321C12N2310/3233C12N2310/3513C12N2310/531C12N2320/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,988,628
App. No.
15/047,258
Granted
Jun 5, 2018
Kind
B2
Abstract

The invention teaches antisense agents and RNA interference agents useful for treating diseases and conditions the treatment of which can benefit from reducing the expression of double homeobox 4 and/or double homeobox 4c, more particularly facioscapulohumeral muscular dystrophy. Further elaborated are methods, uses and further products employing such agents.

Claims (2)

1. An antisense agent, or pharmaceutically acceptable salt thereof, wherein the agent is 25 nucleotides in length and comprises the sequence GGGCAUUUUAAUAUAUCUCUGAACU (SEQ ID NO: 65), in which U bases are T bases, and wherein the antisense agent is a phosphorodiamidate morpholino oligomer.

2. The antisense agent according to claim 1 , wherein the antisense agent is conjugated to a polyethylene glycol chain.

Assignments (1)
SECURITY INTEREST Recorded Jun 27, 2025
From: DYNE THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 071777/0300 →
Priority Claims (1)
EP 10175125 · Sep 2, 2010 · regional
Continuity (3)
Continuation 14078133 · Nov 12, 2013
Division 13225384 · Sep 2, 2011
Related Publication 20170029814A1 · Feb 2, 2017